Get the Stockscreener App
1.9316
3.74%
0.0616
Accelerate Diagnostics Inc stock is traded at $1.9316, with a volume of 14,632.
It is up +3.74% in the last 24 hours and down -0.51% over the past month.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
See More
Previous Close:
$1.87
Open:
$1.87
24h Volume:
14,632
Relative Volume:
0.22
Market Cap:
$44.28M
Revenue:
$12.00M
Net Income/Loss:
$-63.23M
P/E Ratio:
-0.2454
EPS:
-7.87
Net Cash Flow:
$-43.02M
1W Performance:
+4.86%
1M Performance:
-0.51%
6M Performance:
+109.78%
1Y Performance:
-66.89%
1-Day Range:
$1.87
$1.9499
1-Week Range:
$1.80
$1.9499
52-Week Range:
$0.73
$6.20
Accelerate Diagnostics Inc Stock (AXDX) Company Profile
Name
Accelerate Diagnostics Inc
Sector
Industry
Phone
303-863-8088
Address
3950 S. COUNTRY CLUB ROAD #470, TUCSON, AZ
Accelerate Diagnostics Inc Stock (AXDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-22 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-08-20 | Initiated | BTIG Research | Neutral |
| Aug-07-20 | Upgrade | Craig Hallum | Hold → Buy |
| Sep-27-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-18 | Initiated | Craig Hallum | Hold |
| Dec-13-17 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-12-17 | Resumed | BTIG Research | Buy |
| Mar-24-16 | Initiated | JP Morgan | Overweight |
| Dec-16-15 | Initiated | Piper Jaffray | Overweight |
View All
Accelerate Diagnostics Inc Stock (AXDX) Latest News
BNGOBionano Genomics, Inc. Latest Stock News & Market Updates - StockTitan
Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies - PR Newswire
StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
AXDXAccelerate Diagnostics, Inc. Latest Stock News & Market Updates - StockTitan
Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results - StockTitan
Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Comparing Accelerate Diagnostics (NASDAQ:AXDX) & Advanced BioMedical Technologies (OTCMKTS:ABMT) - Defense World
Antimicrobial Resistance Diagnostics Market to Witness an Outstanding Growth by 2032 - openPR
Antibiotic Sensitivity Testing Market Growth and Industry Overview - News in Assen
Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com - Defense World
Optical Imaging Market Size to Reach USD 5.61 Billion by 2033 | Straits Research - GlobeNewswire
Cytovale Completes $100 Million Series D Funding to Accelerate Commercial Expansion of its Rapid Sepsis Solution - PR Newswire
Saudi Arabia Diagnostic Imaging Market Will Accelerate Rapidly - openPR
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System - Yahoo Finance
FDA approves Accelerate Arc system to identify microbial infections - Medical Device Network
FDA clears new system for rapid sepsis identification By Investing.com - Investing.com Australia
FDA clears new system for rapid sepsis identification - Investing.com
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System - StockTitan
Short Interest in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Drops By 12.6% - Defense World
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Stake Reduced by Armistice Capital LLC - Defense World
StockNews.com Initiates Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Italy Antimicrobial Resistance Diagnostics Market Size & Outlook, 2030 - Grand View Research
North America Antimicrobial Resistance Diagnostics Market Size & Outlook, 2030 - Grand View Research
PersonalAIze and Cube Forge Groundbreaking Partnership to - GlobeNewswire
PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics - Yahoo Finance
Accelerate Diagnostics (NASDAQ:AXDX) Stock Crosses Above 200 Day Moving Average of $1.21 - Defense World
Veterinary Antimicrobial Susceptibility Testing Market: In-depth Analysis Of Market Trends, Technological A... - WhaTech
Blood Screening Market Advancements Highlighted by Size, Share, Growth Analysis, Business Insights And Fore... - WhaTech
North America Antibiotic Sensitivity Testing Market By Application - Third Eye News
RenovaroCube to Present Cutting-Edge Cancer Diagnostics - GlobeNewswire
Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine - Business Wire
Chlamydia Infection Diagnostics And Therapeutics Global Market 2024Latest Trends, Technological Advancem... - WhaTech
Blood Culture Tests Market 2024: Pioneering Innovations in Diagnostic Healthcare As Discussed In New Market... - WhaTech Technology and Markets News
New Release of Ibex Medical Analytics AI-powered Platform to Accelerate Advancements in Cancer Diagnostics - Business Wire
India Antimicrobial Resistance Diagnostics Market Size & Outlook, 2030 - Grand View Research
In Vitro Diagnostics Market Trends 2024-2033: Overview, Share, Demand, and Outlook - WhaTech
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com - Defense World
Emerging Trends and Opportunities in the Antimicrobial Susceptibility Testing Market - openPR
Accelerate Diagnostics regains Nasdaq compliance - Investing.com
Sepsis Diagnostics Market to Surge at 8.5% CAGR Through 2032Market.us Media - Market.us Media - United States Market News
Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results - Longview News-Journal
Accelerate Diagnostics Inc [AXDX] Insider Mertz Larry Michael sells 361 Shares - Knox Daily
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial - Yahoo Finance Australia
Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns - Yahoo Finance
Latin America Antimicrobial Resistance Diagnostics Market Size & Outlook, 2030 - Grand View Research
Earnings call: Accelerate Diagnostics Q2 2024 results and Wave program update - Investing.com
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q2 2024 Earnings Call Transcript - Insider Monkey
Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript - Seeking Alpha
Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results - Kilgore News Herald
AXDX Stock Earnings: Accelerate Diagnostics Beats EPS, Misses Revenue for Q2 2024 - InvestorPlace
Accelerate Diagnostics: Q2 Earnings Snapshot - CTPost
Accelerate Diagnostics Inc Stock (AXDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Accelerate Diagnostics Inc Stock (AXDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FRANCESCONI LOUISE | Director |
Jun 28 '24 |
Option Exercise |
0.00 |
4,737 |
0 |
33,558 |
| SCHULER JACK W | Director |
Jun 28 '24 |
Option Exercise |
0.00 |
4,737 |
0 |
20,225 |
| BURRIS WAYNE | Director |
May 31 '24 |
Option Exercise |
0.00 |
839 |
0 |
1,678 |
| FRANCESCONI LOUISE | Director |
May 29 '24 |
Option Exercise |
0.00 |
7,894 |
0 |
28,821 |
| Regan Jennifer | Director |
May 29 '24 |
Option Exercise |
0.00 |
12,631 |
0 |
12,631 |
| SCHULER JACK W | Director |
May 29 '24 |
Option Exercise |
0.00 |
7,894 |
0 |
15,488 |
| MASSARANY HANY | Director |
May 29 '24 |
Option Exercise |
0.00 |
7,894 |
0 |
32,154 |
| Mertz Larry Michael | Chief Technology Officer |
May 20 '24 |
Option Exercise |
0.00 |
1,283 |
0 |
82,114 |
| Mertz Larry Michael | Chief Technology Officer |
May 20 '24 |
Sale |
0.88 |
361 |
318 |
81,831 |
| Phillips Jack | Chief Executive Officer |
Apr 17 '24 |
Option Exercise |
0.00 |
59,928 |
0 |
189,654 |
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):